Skip to main content

Advertisement

SpringerLink
Log in

Non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease in the elderly population: a meta-analysis

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Several studies have explored the impact of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Parkinson disease (PD). However, the extent to which NSAIDs may increase or decrease the risk of PD remains unresolved. We, therefore, performed a meta-analysis of relevant studies to quantify the magnitude of the association between NSAID use and PD risk in the elderly population.

Methods

The electronic databases such as PubMed, EMBASE, Scopus, Google Scholar, and Web of Science were used to search the relevant articles published between January 1990 and December 2017. Large (n ≥ 1000) observational design studies with a follow-up at least 1 year were considered. Two authors independently extracted information from the included studies. Random effect model was used to calculate risk ratios (RRs) with 95% confidence interval (Cl).

Results

A total of 17 studies with 2,498,258 participants and nearly 14,713 PD patients were included in the final analysis. The overall pooled RR of PD was 0.95 (95%CI 0.860–1.048) with significant heterogeneity (I2 = 63.093, Q = 43.352, p < 0.0001). In the subgroup analysis, the overall pooled RR of PD was 0.90 (95%CI 0.738–1.109), 0.96 (95%CI 0.882–1.055), and 0.99 (95%CI 0.841–0.982) from the studies of North America, Europe, and Asia. Additionally, long-term use, study design, individual NSAID use, and risk of PD were also evaluated.

Conclusion

Despite the neuroprotective potential of NSAIDs demonstrated in some experimental studies, our findings suggest that there is no association between NSAIDs and the risk of Parkinson disease at the population level. Until further evidence is established, clinicians need to be vigilant ensuring that the use of NSAIDs remains restricted to their approved anti-inflammatory and analgesic effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Poly TN, Islam MM, Walther BA, Yang H-C, Nguyen P-A, Huang C-W, Shabbir S-A, Li Y-CJ (2017) Exploring the association between statin use and the risk of Parkinson’s disease: a meta-analysis of observational studies. Neuroepidemiology 49:142–151

    Article  PubMed  Google Scholar 

  2. Le W, Wu J, Tang Y (2016) Protective microglia and their regulation in Parkinson’s disease. Front Mol Neurosci 9:89

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Solomon DH, Cannon CP, Saperia GM (2014) Nonselective NSAIDs: adverse cardiovascular effects

  4. Kurth T, Hennekens CH, Buring JE, Gaziano JM (2004) Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis. Curr Rheumatol Rep 6:351–356

    Article  PubMed  Google Scholar 

  5. Hennekens CH, Knatterud GL, Pfeffer MA (2004) Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: clinical and research challenges. Diabetes Care 27:2752–2754

    Article  PubMed  Google Scholar 

  6. Teismann P, Ferger B (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson’s disease. Synapse 39:167–174

    Article  CAS  PubMed  Google Scholar 

  7. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease. Ann Neurol 58:963–967

    Article  CAS  PubMed  Google Scholar 

  8. Bornebroek M, De Lau LM, Haag MD, Koudstaal PJ, Hofman A, Stricker BH, Breteler MM (2007) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 28:193–196

    Article  PubMed  Google Scholar 

  9. Gao X, Chen H, Schwarzschild MA, Ascherio A (2011) Use of ibuprofen and risk of Parkinson disease. Neurology 76:863–869

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hirsch EC, Vyas S, Hunot S (2012) Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord 18:S210–S212

    Article  PubMed  Google Scholar 

  11. Maharaj D, Saravanan K, Maharaj H, Mohanakumar K, Daya S (2004) Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Neurochem Int 44:355–360

    Article  CAS  PubMed  Google Scholar 

  12. Aubin N, Curet O, Deffois A, Carter C (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 71:1635–1642

    Article  CAS  PubMed  Google Scholar 

  13. Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP (2003) Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 966:245–252

    Article  CAS  PubMed  Google Scholar 

  14. Przybyłkowski A, Kurkowska-Jastrzebska I, Joniec I, Ciesielska A, Członkowska A, Członkowski A (2004) Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson’s disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine administration to mouse. Brain Res 1019:144–151

    Article  CAS  PubMed  Google Scholar 

  15. Bower J, Maraganore D, Peterson B, Ahlskog J, Rocca WA (2006) Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 67:494–496

    Article  CAS  PubMed  Google Scholar 

  16. Samii A, Etminan M, Wiens MO, Jafari S (2009) NSAID use and the risk of Parkinson’s disease. Drugs Aging 26:769–779

    Article  CAS  PubMed  Google Scholar 

  17. Gagne JJ, Power MC (2010) Anti-inflammatory drugs and risk of Parkinson disease a meta-analysis. Neurology 74:995–1002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100

    Article  PubMed  PubMed Central  Google Scholar 

  19. Higgins JP, Green S (2005) Cochrane handbook for systematic reviews of interventions. version

  20. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560

    Article  PubMed  PubMed Central  Google Scholar 

  21. Islam MM, Iqbal U, Walther B, Atique S, Dubey NK, Nguyen P-A, Poly TN, Masud JHB, Li Y-CJ, Shabbir S-A (2016) Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis. Neuroepidemiology 47:181–191

    Article  PubMed  Google Scholar 

  22. Becker C, Jick S, Meier C (2011) NSAID use and risk of Parkinson disease: a population-based case-control study. Eur J Neurol 18:1336–1342

    Article  CAS  PubMed  Google Scholar 

  23. Chen H, Zhang SM, Hernán MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60:1059–1064

    Article  PubMed  Google Scholar 

  24. Driver JA, Logroscino G, Lu L, Gaziano JM, Kurth T (2011) Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study. Bmj 342:d198

    Article  PubMed  PubMed Central  Google Scholar 

  25. Etminan M, Carleton BC, Samii A (2008) Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study. J Clin Neurosci 15:576–577

    Article  CAS  PubMed  Google Scholar 

  26. Etminan M, Suissa S (2006) NSAID use and the risk of Parkinson’s disease. Curr Drug Saf 1:223–225

    Article  CAS  PubMed  Google Scholar 

  27. Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK (2007) Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 64:576–580

    Article  PubMed  Google Scholar 

  28. Hernán MA, Logroscino G, Rodríguez LAG (2006) Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 66:1097–1099

    Article  PubMed  Google Scholar 

  29. Lin CH, Wu RM, Chang HY, Chiang YT, Lin HH (2013) Preceding pain symptoms and Parkinson’s disease: a nationwide population-based cohort study. Eur J Neurol 20:1398–1404

    Article  PubMed  Google Scholar 

  30. Manthripragada AD, Schernhammer ES, Qiu J, Friis S, Wermuth L, Olsen JH, Ritz B (2011) Non-steroidal anti-inflammatory drug use and the risk of Parkinson’s disease. Neuroepidemiology 36:155–161

    Article  PubMed  PubMed Central  Google Scholar 

  31. Powers KM, Kay DM, Factor SA, Zabetian CP, Higgins DS, Samii A, Nutt JG, Griffith A, Leis B, Roberts JW (2008) Combined effects of smoking, coffee, and NSAIDs on Parkinson’s disease risk. Mov Disord 23:88–95

    Article  PubMed  Google Scholar 

  32. Sung Y-F, Liu F-C, Lin C-C, Lee J-T, Yang F-C, Chou Y-C, Lin C-L, Kao C-H, Lo H-Y, Yang T-Y (2016) Reduced risk of Parkinson disease in patients with rheumatoid arthritis: a nationwide population-based study. Mayo Clinic Proceedings. Elsevier, pp 1346–1353

  33. Ton TG, Heckbert SR, Longstreth W, Rossing MA, Kukull WA, Franklin GM, Swanson PD, Smith-Weller T, Checkoway H (2006) Nonsteroidal anti-inflammatory drugs and risk of Parkinson’s disease. Mov Disord 21:964–969

    Article  PubMed  Google Scholar 

  34. Wahner AD, Bronstein JM, Bordelon YM, Ritz B (2007) Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69:1836–1842

    Article  CAS  PubMed  Google Scholar 

  35. Kurkowska-Jastrzębska I, Babiuch M, Joniec I, Przybyłkowski A, Członkowski A, Członkowska A (2002) Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. Int Immunopharmacol 2:1213–1218

    Article  PubMed  Google Scholar 

  36. Mohanakumar KP, Muralikrishnan D, Thomas B (2000) Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity. Brain Res 864:281–290

    Article  CAS  PubMed  Google Scholar 

  37. Eccleston C, Cooper TE, Fisher E, Anderson B, Wilkinson NM (2017) Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. Cochrane Database Syst Rev

  38. Teismann P, Tieu K, Choi D-K, Wu D-C, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S (2003) Cyclooxygenase-2 is instrumental in Parkinson’s disease neurodegeneration. Proc Natl Acad Sci 100:5473–5478

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Sánchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell A-L, Isacson O (2004) Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson’s disease. J Neuroinflammation 1:6

    Article  PubMed  PubMed Central  Google Scholar 

  40. Wang T, Pei Z, Zhang W, Liu B, Langenbach R, Lee C, Wilson B, Reece JM, Miller DS, Hong J-S (2005) MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J 19:1134–1136

    Article  CAS  PubMed  Google Scholar 

  41. Carrasco E, Casper D, Werner P (2005) Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity. J Neurosci Res 81:121–131

    Article  CAS  PubMed  Google Scholar 

  42. Sostres C, Gargallo CJ, Arroyo MT, Lanas A (2010) Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 24:121–132

    Article  CAS  PubMed  Google Scholar 

  43. Bessone F (2010) Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J Gastroenterol: WJG 16:5651–5661

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was financially supported by the “TMU Research Center of Cancer Translational Medicine” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.

Author information

Author notes

  1. Hsuan-Chia Yang and Yu-Chuan Jack Li contributed equally to this work.

Authors and Affiliations

  1. Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, 250 Wu-Hsing Street, Taipei, 110, Taiwan

    Tahmina Nasrin Poly, Md. Mohaimenul (Rubel) Islam & Yu-Chuan Jack Li

  2. International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan

    Tahmina Nasrin Poly, Md. Mohaimenul (Rubel) Islam, Hsuan-Chia Yang & Yu-Chuan Jack Li

  3. Department of Dermatology, Wan Fang Hospital, Taipei, Taiwan

    Yu-Chuan Jack Li

  4. TMU Research Center of Cancer Translational Medicine, Taipei, Taiwan

    Yu-Chuan Jack Li

Authors
  1. Tahmina Nasrin Poly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Md. Mohaimenul (Rubel) Islam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hsuan-Chia Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu-Chuan Jack Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu-Chuan Jack Li.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

This study has been approved by our Institution’s Ethics Committee and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

Electronic supplementary material

ESM 1

(DOCX 209 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Poly, T.N., Islam, M.M.(., Yang, HC. et al. Non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease in the elderly population: a meta-analysis. Eur J Clin Pharmacol 75, 99–108 (2019). https://doi.org/10.1007/s00228-018-2561-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-018-2561-y

Keywords

Search

Navigation